MUMBAI — India’s unregulated sale of GLP-1 receptor agonists for weight loss is exposing patients to serious health risks, as clinics and online pharmacies dispense the powerful drugs without clinical oversight, medical monitoring, or behavioral support, according to healthcare professionals and public health advocates.
Originally developed to treat type 2 diabetes, GLP-1 drugs such as semaglutide (marketed as Ozempic and Wegovy) and liraglutide (Saxenda) have become sought-after weight-loss solutions after clinical trials demonstrated reductions in body weight of 10–15%. In India, where obesity now affects 23% of urban adults, these medications are being aggressively marketed—often as quick-fix solutions—without the infrastructure needed to ensure safe and effective use.
What Happened
In early 2026, a survey by the Obesity and Metabolic Surgery Society of India (OSSI) revealed alarming patterns in the use of GLP-1 drugs. Of 1,200 patients who obtained the medications online, 42% did so without a prescription, and 68% received no follow-up care. Nearly one-third reported severe side effects, including persistent vomiting, dehydration, and in some cases, hospitalization. The findings underscore a growing disconnect between the medical promise of GLP-1 drugs and their real-world application in India’s largely unregulated healthcare marketplace.
The Drugs Controller General of India (DCGI) has approved semaglutide only for diabetes management, not for obesity. However, off-label use for weight loss remains legal and unmonitored. With generic versions now available, prices have fallen sharply, making the drugs more accessible—but also increasing the risk of misuse. Online platforms, in particular, have come under scrutiny for selling GLP-1 drugs without requiring prescriptions, medical evaluations, or post-treatment monitoring.
“These are not over-the-counter supplements,” said Dr. Anjali Deshpande, an endocrinologist at Mumbai’s Lilavati Hospital. “GLP-1 agonists alter core metabolic pathways. They can cause pancreatitis, thyroid tumors, and severe gastrointestinal distress. Selling them without clinical oversight is not just unethical—it’s dangerous.”
Why It Matters
Obesity is recognized by the World Health Organization (WHO) as a chronic, relapsing disease linked to diabetes, cardiovascular disease, and several cancers. Effective treatment requires a multidisciplinary approach, including nutrition counseling, behavioral therapy, physical activity, and medical management. GLP-1 drugs, when used appropriately, can be a valuable tool—but only as part of a broader care plan.
The current commercial model, however, reduces obesity treatment to a transaction. “This is not obesity care,” said Dr. Ramen Goel, president of OSSI. “It’s pharmaceutical profiteering. Obesity is a complex, multifactorial condition. Reducing it to a pill without addressing behavior, psychology, or metabolism is a disservice to patients and a distortion of medicine.”
The absence of national guidelines from the Indian Council of Medical Research (ICMR) has created a regulatory vacuum. While the Ministry of Health and Family Welfare has acknowledged the rise in off-label use, it has not yet issued formal protocols for prescribing GLP-1 drugs for weight loss. This gap has allowed private clinics and digital health platforms to operate without accountability, prioritizing sales over patient safety.
Background and Context
GLP-1 receptor agonists work by mimicking the glucagon-like peptide-1 hormone, which regulates appetite and insulin secretion. In clinical settings, they are administered via injection and require dose titration to minimize side effects. Long-term use is often necessary to maintain weight loss, and discontinuation frequently leads to rebound weight gain.
In India, the commercialization of GLP-1 drugs has accelerated alongside the rise of telemedicine and e-pharmacies. While these platforms have improved access to healthcare in underserved areas, they have also enabled the unchecked distribution of prescription-only medications. A 2025 report by the Federation of Indian Chambers of Commerce and Industry (FICCI) found that 63% of online pharmacy transactions for weight-loss drugs involved no medical consultation.
The global market for GLP-1 drugs is projected to exceed $150 billion by 2030, driven by demand in the U.S., Europe, and Asia. In India, where generic manufacturers have entered the market, prices have dropped from over ₹20,000 per month to as low as ₹3,500, making the drugs affordable for middle-class consumers. However, affordability has not been matched by accountability.
Competing Claims and Uncertainty
Pharmaceutical companies and digital health platforms argue that GLP-1 drugs are empowering patients to take control of their health. “These medications are transforming lives,” said a spokesperson for Novo Nordisk India, which manufactures semaglutide. “We support responsible use and are working with healthcare providers to ensure safe access.”
However, medical associations counter that responsibility cannot be outsourced to patients. “The burden of monitoring side effects, adjusting dosages, and providing behavioral support cannot fall on individuals,” said Dr. Shashank Joshi, a senior endocrinologist and advisor to the Indian government on metabolic health. “These drugs require clinical infrastructure. Without it, we’re not treating obesity—we’re creating a new set of health problems.”
There is also uncertainty about the long-term effects of widespread GLP-1 use. While clinical trials have demonstrated safety over 2–3 years, real-world data from unsupervised use is lacking. Some experts warn of potential risks, including muscle loss, nutritional deficiencies, and psychological dependence on medication.
What to Watch Next
Public health advocates are calling for urgent regulatory action. Key developments to monitor include:
– ICMR Guidelines: The Indian Council of Medical Research is expected to release its first national guidelines on the use of GLP-1 drugs for obesity by mid-2026. These are likely to include requirements for medical evaluation, follow-up care, and integration with lifestyle programs.
– DCGI Oversight: The Drugs Controller General of India may issue new rules restricting the sale of GLP-1 drugs to licensed clinics and requiring prescriptions for all purchases, including online.
– E-Pharmacy Regulations: The Ministry of Health is reviewing draft rules to mandate in-person consultations for high-risk medications, including GLP-1 agonists. If implemented, these could significantly reduce unsupervised sales.
– Pharmaceutical Accountability: Novo Nordisk and Eli Lilly, the leading manufacturers of GLP-1 drugs, are under pressure to implement patient support programs in India, including monitoring tools and educational resources.
– Public Awareness Campaigns: Medical associations, including OSSI and the Endocrine Society of India, are planning nationwide campaigns to educate patients about the risks of self-medicating with GLP-1 drugs.
Conclusion
The rapid commercialization of GLP-1 drugs in India presents a paradox: a medical breakthrough with the potential to address a major public health challenge is being deployed in ways that may undermine its own promise. While these medications offer real hope for millions struggling with obesity, their unregulated use risks turning a therapeutic advance into a public health liability.
The current crisis is not just about a single class of drugs—it reflects broader tensions in modern healthcare: the balance between innovation and safety, access and accountability, profit and patient welfare. For India, the path forward requires more than regulation. It demands a redefinition of obesity care—one that treats the disease with the complexity it deserves, not as a commodity to be sold.
As Dr. Joshi put it: “We have the tools to fight obesity. But tools alone are not enough. We need the infrastructure, the expertise, and the ethics to use them wisely.”
Story synopsis gathered from: Express Healthcare — [source](https://news.google.com/rss/articles/CBMitwFBVV95cUxPUG1lS3dDS3ZHZFp0bmgxNmNkU012TGYxcDh1T3pQWDgzZ1J4STUzSWxjMjlFc2JiYUlET3pjM0QxWXVDc1UtVlAtVmZBbHZ2Q1AxLVppODNNNUpiZC1TaW5GUjFHVDluRHNLRnNqcVlMMVh5b21aY3dYZTZCb2dvbDdVeWUtdkh2UG1UZ180Rzh4RFpqUk1VTVl4ZzJYN24wbVBtdjNITm1ZZFJpa1VSazN3cmVNR2M?oc=5).
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Google News India – Top Stories — source.
